Breast Cancer：Prognosis, Treatment, and Prevention

Now in its second edition, this bestselling title has been extensively revised and expanded to include new topics on:

• obesity and breast cancer
• induction of anti-hormone and anti-growth factor resistance in breast cancer
• clinical implications of testosterone and breast cancer
• insulin-like growth factors
• discussions on the biological, genetic, and molecular pathways linked to the development and progression of breast cancer
• analyses on the latest therapeutic strategies, prognostic and predictive factors, and prevention strategies

Examining new developments, Breast Cancer: Prognosis, Treatment, and Prevention, Second Edition also covers:

• the mechanism involved in carcinogenesis
• the relationship among a fetus, pregnancy, and breast cancer
• recent developments in endocrine treatment
• the relationship among hormone replacement therapy, cytotoxic therapy, and other non-hormonal approaches for the treatment of metastases
• management of locally advanced breast cancer, and the importance of BRCA-1 and BRCA-2 in hereditary breast cancer

With new topics and updated chapters, this new edition keeps both oncologists and radiologists abreast of the current trends and advancements in the prognosis, treatment, and prevention of breast cancer.

JORGE R. PASQUALINI is Director of the Hormones and Cancer Research Unit at the Institut de Puericulture of Paris. Professor Pasqualini received his Ph.D. in biology from the University of Buenos Aires, Argentina, and a D.Sc. degree in Endocrinology from the University of Paris, France. He has published more than 600 original papers and is the founder and Editor-in-Chief of The Journal of Steroid Biochemistry and Molecular Biology, which is considered to be one of the leading international scientific journals in the field. Professor Pasqualini has worked in varying areas of endocrinology and reproduction, and in recent years found new aspects of the production, control, and biological effect of estrogens, anti-estrogens, and progestins in human breast and endometrial cancers, with potential clinical applications in pre- and postmenopausal patients.